Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on β-adrenoceptor signaling in heart failure produced by myocardial infarction in rabbits: Reversal of altered expression of β-adrenoceptor kinase and Giα

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 370-379

  Makino, Takao ^a   Hattori, Yuichi ^a   Matsuda, Naoyuki ^a   Onozuka, Hisao ^a   Sakuma, Ichiro ^a   Kitabatake, Akira ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; TEMOCAPRIL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG BINDING; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HUMAN; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADENYLATE CYCLASE; ADRENERGIC BETA-AGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; BLOTTING, WESTERN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; ECHOCARDIOGRAPHY; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; IODOCYANOPINDOLOL; MALE; MEMBRANES; MYOCARDIAL INFARCTION; MYOCARDIUM; NOREPINEPHRINE; ORGAN SIZE; RABBITS; RADIOLIGAND ASSAY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; THIAZEPINES;

EID: 0037216622     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.040956     Document Type: Article

References (40)

1. Bokoch GM, Katada T, Northup JK, Ui M, and Gilman AG (1984) Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J Biol Chem 259:3560-3567.
2. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, and Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205-211.
3. 1-receptor down-regulation in heart failure. Circ Res 59:297-309.
4. Brodde OE, Michel MC, and Zerkowski HR (1995) Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 30:570-584.
5. Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, and Zelis R (1994) Prejunctional angiotensin II receptors. J Clin Invest 93:684-691.
6. Cohn JN and Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675.
7. 1-receptor subtype. Br J Pharmacol 110:761-771.
8. iα-2 in human end-stage heart failure. Circ Res 70:688-696.
9. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, and Van Dop C (1988) Increase of the 40, 000-mol.wt. pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82:189-197.
10. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, and Bristow MR (1993) Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 88:472-480.
11. Hatta E, Rubin LE, Seyedi N, and Levi R (1997) Bradykinin and cardioprotection: Don't set your heart on it. Pharmacol Res 35:531-536.
12. Hattori Y, Sakuma I, Nakao Y, and Kanno M (1987) Pharmacological analysis of the cardiac actions of xamoterol, a β adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: Evidence for involvement of adenylate cyclase system in its cardiac stimulant actions. J Pharmacol Exp Ther 242:1077-1085.
13. Hausdorff WP, Caron MG, and Lefkowitz RJ (1990) Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J 4:2881-2889.
14. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, and Fowler MB (1989) Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79:483-490.
15. Hirsch AT, Talsness CE, Schunkert H, Paul M, and Dzau VJ (1991) Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69:475-482.
16. Holmer SR, Stevens S, and Homcy CJ (1989) Tissue- and species-specific expression of inhibitory guanine nucleotide-binding proteins: Cloning of a full-length complementary DNA from canine heart. Circ Res 65:1136-1140.
17. Hosono M, Takahira T, Fujita A, Fujihara R, Ishizuka O, Ohoi I, Tatee T, and Nakamura K (1990) Cardiovascular effects of NKH477, a novel potent water-soluble forskolin derivative. Eur J Pharmacol 83:2110-2111.
18. Iaccarino G, Tomhave ED, Lefkowitz RJ, and Koch WJ (1998) Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98:1783-1789.
19. Inglese J, Freedman NJ, Koch WJ, and Lefkowitz RJ (1993) Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem 268:23735-23738.
20. Ishigai Y, Mori T, Moriyama S, and Shibano T (1999) Induction of cardiac β-adrenergic receptor kinase 1 in rat heart failure caused by coronary ligation. J Moll Cell Cordial 31:1261-1268.
21. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. sα in septic rabbits. Anesthesiology 93:1465-1473.
23. Maurice JP, Shah AS, Kypson AP, Hata JA, White DC, Glower DD, and Koch WJ (1999) Molecular β-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol 276:H1853-H1860.
24. Oizumi K, Koike H, Sada T, Miyamoto M, Nishio H, Matsushita Y, Iijima Y, and Yanagisawa H (1988) Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. Jpn J Pharmacol 48:349-356.
25. Pennock GD, Yun DD, Agarwal PG, Spooner PH, and Goldman S (1997) Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction. Am J Physiol 273:H2018-H2029.
26. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.
27. Roth DA, Urasawa K, Helmer GA, and Hammond HK (1993) Down-regulation of cardiac guanosine 5′-triphosphate-binding proteins in right atrium and left ventricle in pacing-induced congestive heart failure. J Clin Invest 91:939-949.
28. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, and Goldstein S (1994) Effects of long-term monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89:2852-2859.
29. Salomon Y, Londos C, and Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
30. Sanbe A and Takeo S (1995) Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac β-adrenoceptor responses in rats with chronic heart failure. Circulation 92:2666-2675.
31. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, and Drexler H (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89:2273-2282.
32. Spinale FG, Holzgrefe HH, Mukherjee R, Webb ML, Hird RB, Cavallo MJ, Powell JR, and Koster WH (1997) Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: Differential effects on myocyte contractile processes. J Pharmacol Exp Ther 283:1082-1094.
33. St. John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, et al. (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89:68-75.
34. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435.
35. 1-adrenergic receptors in the failing human heart. Circulation 87:454-463.
36. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, and Richardt G (1996) Activation of β-adrenergic receptor kinase during myocardial ischemia. Circ Res 79:455-460.
37. Ungerer M, Parruti G, Böhm M, Puzicha M, DeBlasi A, Erdmann E, and Lohse MJ (1994) Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res 74:206-213.
38. i2, a GTP-binding signal transduction protein. FEBS Lett 232:333-340.
39. Wilson CJ and Applebury ML (1993) Arresting G-protein coupled receptor activity. Curr Biol 3:683-686.
40. Yoshida H, Takahashi M, Tanonaka K, Maki T, Nasa Y, and Takeo S (2001) Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol 134:150-160.